Larimar Net Working Capital from 2010 to 2024

LRMR Stock  USD 9.41  0.28  2.89%   
Larimar Therapeutics Net Working Capital yearly trend continues to be relatively stable with very little volatility. Net Working Capital is likely to drop to about 75.2 M. During the period from 2010 to 2024, Larimar Therapeutics Net Working Capital destribution of quarterly values had range of 111.2 M from its regression line and mean deviation of  37,685,220. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
80.7 M
Current Value
75.2 M
Quarterly Volatility
42.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Larimar Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Larimar Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 472.6 K, Selling General Administrative of 8.8 M or Other Operating Expenses of 38.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.32. Larimar financial statements analysis is a perfect complement when working with Larimar Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Larimar Therapeutics Correlation against competitors.
To learn how to invest in Larimar Stock, please use our How to Invest in Larimar Therapeutics guide.

Latest Larimar Therapeutics' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Larimar Therapeutics over the last few years. It is Larimar Therapeutics' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Larimar Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Larimar Net Working Capital Regression Statistics

Arithmetic Mean27,118,915
Geometric Mean4,759,614
Coefficient Of Variation156.39
Mean Deviation37,685,220
Median(1,145,000)
Standard Deviation42,410,929
Sample Variance1798.7T
Range111.2M
R-Value0.79
Mean Square Error714.4T
R-Squared0.63
Significance0.0004
Slope7,534,322
Total Sum of Squares25181.6T

Larimar Net Working Capital History

202475.2 M
202380.7 M
2022110 M
202163.4 M
202089 M

About Larimar Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Larimar Therapeutics income statement, its balance sheet, and the statement of cash flows. Larimar Therapeutics investors use historical funamental indicators, such as Larimar Therapeutics's Net Working Capital, to determine how well the company is positioned to perform in the future. Although Larimar Therapeutics investors may use each financial statement separately, they are all related. The changes in Larimar Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Larimar Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Larimar Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Larimar Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital80.7 M75.2 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Tools for Larimar Stock Analysis

When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.